What is Newcells Biotech?
Originating as a spin-out from Newcastle University, Newcells Biotech operates at the intersection of stem cell biology and pharmaceutical innovation. The company provides specialized, high-fidelity human cell models designed to accelerate the drug discovery process, effectively reducing the reliance on traditional, less predictive testing methods. By utilizing expertise from one of the UK's most prominent centers for stem cell research, the firm offers pharmaceutical partners a robust framework for evaluating drug efficacy and toxicity early in the development pipeline. This market position allows Newcells Biotech to serve as a critical enabler for global pharmaceutical companies seeking to improve the success rates of new therapeutic candidates.
How much funding has Newcells Biotech raised?
Newcells Biotech has raised a total of $11.2M across 3 funding rounds:
Other Financing Round
$7.4M
Other Financing Round
$2.4M
Other Financing Round
$1.5M
Other Financing Round (2021): $7.4M with participation from Mercia Asset Management and North East Innovation Fund
Other Financing Round (2024): $2.4M led by The European Regional Development Fund
Other Financing Round (2024): $1.5M supported by Mercia Group, Northstar Ventures, and North East Finance
Key Investors in Newcells Biotech
Mercia Group
Mercia Group provides comprehensive training and support services for accounting professionals, while also operating as a significant investment firm focused on regional business growth.
Northstar Ventures
Northstar Ventures is a dedicated venture capital firm focused on building high-growth businesses in the North East of England, often managing funds backed by the European Investment Bank.
North East Finance
North East Finance specializes in managing and overseeing investments from publicly backed funds to support the growth and development of small and medium-sized enterprises.
What's next for Newcells Biotech?
With the recent influx of $1.5M, Newcells Biotech is well-positioned to expand its laboratory infrastructure and broaden its portfolio of human cell-based assays. The strategic focus will likely shift toward scaling commercial operations and deepening partnerships with international pharmaceutical entities. As the company matures, the integration of these funds will facilitate the development of next-generation screening technologies, further cementing its role as a vital contributor to the efficiency of the drug development lifecycle. The firm remains focused on long-term value creation, leveraging its unique intellectual property to address the evolving needs of the global healthcare industry.
See full Newcells Biotech company page
